Seeking Alpha

Hospira (HSP -5.7%) takes a hit today after posting better-than-expected Q4 results, but issuing...

Hospira (HSP -5.7%) takes a hit today after posting better-than-expected Q4 results, but issuing a disappointing outlook for FY13. Net earnings swung to a profit amid stronger sales of its specialty drugs and the impact of a major write-down in the prior-year period, but the company warns that FY13 will be burdened by ongoing heavy costs to resolve regulatory concerns over manufacturing at some of its plants. It now expects to earn between $2.05 to $2.20 on net sales growth of 1% to 3%, below estimates of $2.31 on revenue growth of 4%.
Comments (1)
  • Bipolar company, bipolar management: re read the Q4 transcript bearing in mind my comment. Is it a fit for a company trying to expand in the US?
    18 Feb 2013, 08:26 AM Reply Like
DJIA (DIA) S&P 500 (SPY)